Literature DB >> 11516107

T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.

M J Cantwell1, W G Wierda, I S Lossos, R Levy, T J Kipps.   

Abstract

Purified, high-titer adenovirus encoding murine CD154 (Ad-CD154) or human CD154 (Ad-hCD154) was used to infect lymph node cells isolated from patients with follicle center lymphoma. Infection of lymphoma B cells with Ad-CD154 at a multiplicity of infection (MOI) ratio of 100 or higher resulted in high-level transgene expression. Additionally, upon infection of lymphoma B cells, only Ad-CD154 resulted in surface expression of CD154, despite similar, high-level expression of either human or mouse CD154 by HeLa cells infected with Ad-hCD154 or Ad-CD154, respectively. Moreover, infection of lymphoma B cells with Ad-CD154, but not Ad-hCD154 or adenovirus encoding Eschericheria coli beta-galactosidase (Ad-LacZ), induced the neoplastic B cells to express higher levels of immune co-stimulatory molecules that are required for proficient presentation of antigen to T cells. Consistent with this, we found that Ad-CD154 infected lymphoma B cells could stimulate T cells to proliferate or produce interferon-gamma in allogeneic or autologous mixed lymphocyte interactions. We conclude that lymphoma B cells can be infected with Ad-CD154 and that this significantly enhances their recognition by allogeneic or autologous T cells. As such, Ad-CD154-transduced lymphoma B cells may have potential for the active immune therapy of patients with follicle center lymphoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516107     DOI: 10.1038/sj.leu.2402208

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  3 in total

1.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

2.  In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Authors:  Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam Levitsky; Eduardo M Sotomayor
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

3.  Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.

Authors:  Mauricio Urquiza; Johanna Melo-Cardenas; Robier Aguillon; Thomas J Kipps; Januario E Castro
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.